title: Temozolomide treatment for aggressive pituitary tumors: correlation of clinical outcome with O(6)-methylguanine methyltransferase (MGMT) promoter methylation and expression.
abstract: BACKGROUND
  The typically indolent behavior of pituitary tumors is juxtaposed with high rates of tumor cell invasion into adjacent dural structures, and occasional aggressive behavior. Although clinically significant invasion and malignant transformation remain uncommon, there are limited treatment options available for the management of these aggressive tumors. Recently, case reports have described efficacy of temozolomide for the treatment of aggressive pituitary tumors.
  
  
  METHODS
  Seven patients with aggressive pituitary tumors have been treated with temozolomide. We compared O(6)-methylguanine methyltransferase (MGMT) promoter methylation and MGMT expression in 14 surgical specimens from these seven patients and correlated these molecular features with the clinical response to temozolomide.
  
  
  RESULTS
  Significant tumor regression was seen in two patients (29%), a 20% reduction in tumor volume with subsequent stable tumor size was noted in one patient, arrest of tumor growth occurred in three patients, and progressive metastatic disease developed during treatment in one patient. The DNA promoter site for MGMT was unmethylated in all 14 adequate specimens, and variable MGMT expression was seen in all 14 cases. There was no correlation between MGMT expression and clinical outcomes.
  
  
  CONCLUSIONS
  We conclude that medical therapy with temozolomide can be helpful in the management of life-threatening pituitary tumors that have failed to respond to conventional treatments. The optimal duration of treatment in patients with stabilization or reduction of tumor size has not been established, and long-term follow up studies are needed.
authors.affiliation: Division of Endocrinology and Metabolism, University of Virginia, Charlottesville, Virginia 22908-0214, USA.
authors.forename: Zachary M
authors.initials: ZM
authors.lastname: Bush
authors.forename: Janina A
authors.initials: JA
authors.lastname: Longtine
authors.forename: Tracy
authors.initials: T
authors.lastname: Cunningham
authors.forename: David
authors.initials: D
authors.lastname: Schiff
authors.forename: John A
authors.initials: JA
authors.lastname: Jane
authors.forename: Mary Lee
authors.initials: ML
authors.lastname: Vance
authors.forename: Michael O
authors.initials: MO
authors.lastname: Thorner
authors.forename: Edward R
authors.initials: ER
authors.lastname: Laws
authors.forename: M Beatriz S
authors.initials: MB
authors.lastname: Lopes
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D019175:DNA Methylation; D003606:Dacarbazine / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006801:Humans; D007150:Immunohistochemistry; D019853:O(6)-Methylguanine-DNA Methyltransferase / Q000235:genetics* / Q000378:metabolism; D010911:Pituitary Neoplasms / Q000188:drug therapy* / Q000235:genetics* / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011401:Promoter Regions, Genetic; D000077204:Temozolomide; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D003606:Dacarbazine; D019853:O(6)-Methylguanine-DNA Methyltransferase; D000077204:Temozolomide